Adam Robertson
Chief Scientific Officer Hemispherian
Adam Robertson, PhD, is Chief Scientific Officer at Hemispherian, a Norwegian biotech company developing epigenetic cancer therapeutics for aggressive cancers such as glioblastoma. With over 20 years of experience in drug discovery and molecular biology, Adam leads R&D efforts from target validation to clinical readiness, advancing Hemispherian’s novel GLIX compounds designed to exploit DNA damage response mechanisms and improve patient outcomes.
Seminars
Tuesday 5th May 2026
Advancing Targeted DNA Damage Therapy for Glioblastoma – From Preclinical Success to Clinical Trials
10:00 am
- Discussing the rationale behind applying orthotopic xenograft models to empower small molecule development to better treat glioblastoma
- Demonstrating potent anti-tumour activity of this small molecule in multiple glioblastoma models with strong blood-brain barrier penetration and favourable safety in toxicology studies
- Leveraging these preclinical findings to build a strong IND package and begin treating patients with high unmet medical need with the hope of better understanding the translational relevance of these models
